HeartFlow, Inc. (HTFL)
| Market Cap | 1.89B |
| Revenue (ttm) | 161.88M +85.7% |
| Net Income | -125.37M |
| EPS | -7.38 |
| Shares Out | 85.16M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,622,286 |
| Open | 24.87 |
| Previous Close | 25.10 |
| Day's Range | 22.05 - 25.05 |
| 52-Week Range | 20.13 - 41.22 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 39.20 (+76.94%) |
| Earnings Date | Mar 18, 2026 |
About HTFL
HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases worldwide. Its HeartFlow Platform uses AI and computational fluid dynamics to creates a personalized 3D model of a patient’s heart from a single coronary computed tomography angiography, a specialized type of scan that provides detailed images of the heart’s arteries. The company’s platform provides insights on blood flow, stenosis, and plaque volume and composition by overcoming the limitations of traditional non-... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for HTFL stock is "Strong Buy." The 12-month stock price target is $39.2, which is an increase of 76.94% from the latest price.
News
Heartflow to Participate in the Morgan Stanley Technology, Media & Telecom Conference
MOUNTAIN VIEW, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced that members of mana...
2025 U.S. IPO Performance Starts With A Roar And Ends With A Whimper
2025 US IPOs emerged out of a tumultuous April with strong price momentum going into the summer. US IPOs under $100 million in proceeds continued to perform poorly in 2025 after also struggling in 202...
Heartflow to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026
MOUNTAIN VIEW, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release fina...
Baron Opportunity Fund Q4 2025 Portfolio Activity
We invest in secular growth and innovative businesses across all market capitalizations, with the bulk of the portfolio landing in the large-cap zone. We recently initiated a position in Axon Enterpri...
HeartFlow, Inc. (HTFL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
HeartFlow, Inc. (HTFL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Heartflow Plaque Analysis Now Covered by Aetna Insurance Plans Nationwide and for the Majority of Insured Lives in the U.S.
MOUNTAIN VIEW, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced Heartflow Plaque Ana...
Heartflow to Participate in the 44th Annual J.P. Morgan Healthcare Conference
MOUNTAIN VIEW, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in artificial intelligence (AI) technology for coronary artery disease (CAD), today anno...
Heartflow Plaque Analysis Now Supported by Scientific Statements From American College of Cardiology and American Heart Association for Personalized Management of Patients with Suspected CAD
Reinforces Role of AI-Powered Quantitative Coronary Plaque Assessment Reinforces Role of AI-Powered Quantitative Coronary Plaque Assessment
Heartflow FFRCT Analysis Delivers Prognostic Power and Significant Cost Savings in New Analyses of Over 90,000 Patients with Coronary Artery Disease
Lesion-specific FFRCT predicts individual cardiovascular outcomes and delivers greater-than-modeled cost savings for real-world population in FISH&CHIPS analyses from England's National Health Service...
Heartflow to Participate in the Piper Sandler 37th Annual Healthcare Conference
MOUNTAIN VIEW, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in artificial intelligence (AI) technology for coronary artery disease (CAD), today anno...
Heartflow Reports Third Quarter 2025 Financial Results
MOUNTAIN VIEW, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in artificial intelligence (AI) technology for coronary artery disease (CAD), today repo...
Baron Technology Fund: AI Update
The market has recently absorbed a surge of activity around AI infrastructure buildouts. NVIDIA CEO Jensen Huang proclaimed in September that global AI infrastructure spending could total $3 trillion ...
AHA 2025: Late-Breaking Data Reinforce the Prognostic Power of AI-Driven Heartflow Plaque Analysis as the Most Clinically Validated Framework for Coronary Risk Stratification
NEW ORLEANS, Nov. 09, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced late-breaking data from the FI...
Heartflow to Present Late-Breaking Data Advancing AI-Driven Heartflow Plaque Analysis at AHA 2025
MOUNTAIN VIEW, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will present new ...
Heartflow to Report Third Quarter 2025 Financial Results on November 12, 2025
MOUNTAIN VIEW, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release fina...
New Heartflow PCI Navigator to Equip Interventional Cardiologists with Pre-procedural Insights to Enable PCI Planning
PLAN CALCIUM study to be presented at TCT 2025 conference highlights how AI-powered plaque analysis can inform lesion preparation and calcium modification planning NAVIGATE-PCI registry to enroll appr...
Heartflow Announces FDA 510(k) Clearance and Launch of Next Generation Heartflow Plaque Analysis Platform
AI-Powered Heartflow Plaque Analysis to be Covered by Cigna Health Plans Nationwide AI-Powered Heartflow Plaque Analysis to be Covered by Cigna Health Plans Nationwide
Heartflow to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
MOUNTAIN VIEW, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced that members of mana...
Heartflow, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
MOUNTAIN VIEW, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), a leader in AI technology for coronary artery disease (CAD), today announced the closing of its ups...
HeartFlow: Investors Put Their Heart In
HeartFlow's AI-driven, non-invasive CAD diagnostic platform addresses a large, growing market with significant clinical need and strong early adoption. The IPO valued HeartFlow at $1.5 billion, equal ...
Heartflow Stock Opens Nearly 50% Above IPO Price in Latest Hot Debut
Medical imaging company Heartflow rose nearly 50% on its first day, joining Firefly, Figma, and Circle as big IPO gainers.
Medtech firm Heartflow gains 47% in solid Nasdaq debut
Shares of Heartflow rose nearly 47.4% in their Nasdaq debut on Friday, valuing the medical technology company at $2.27 billion.
Medtech firm Heartflow raises $316.7 million in US IPO
Medical technology firm Heartflow said on Thursday it has raised $316.7 million in its U.S. initial public offering.
Heartflow, Inc. Announces Pricing of Upsized Initial Public Offering
MOUNTAIN VIEW, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), a leader in AI technology for coronary artery disease (CAD), today announced the pricing of its ups...
Bain Capital-backed Heartflow targets $1.5 billion valuation in upsized US IPO
Medical technology company Heartflow said on Wednesday it was targeting a valuation of up to $1.46 billion in its upsized initial public offering in the United States, indicating robust investor deman...